Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Linde
LIN
|
+$588M |
| 2 |
Apple
AAPL
|
+$574M |
| 3 |
Illumina
ILMN
|
+$398M |
| 4 |
argenx
ARGX
|
+$306M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$250M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
+$600M |
| 2 |
AbbVie
ABBV
|
+$323M |
| 3 |
Sherwin-Williams
SHW
|
+$309M |
| 4 |
Atlassian
TEAM
|
+$250M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$241M |
Sector Composition
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.43% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
901
Eversource Energy
ES
$23.8B
| $4.54M | ﹤0.01% |
58,040
+10,295
| +22% | +$805K |
|
902
Concentrix
CNXC
$3.25B
| $4.54M | ﹤0.01% |
37,344
+28,460
| +320% | +$3.46M |
|
903
Enphase Energy
ENPH
$4.85B
| $4.51M | ﹤0.01% |
21,461
+2,300
| +12% | +$484K |
|
904
International Flavors & Fragrances
IFF
$16.5B
| $4.49M | ﹤0.01% |
48,862
+17,103
| +54% | +$1.57M |
|
|
VRNA
905
Verona Pharma
VRNA
$9.2B
| $4.48M | ﹤0.01% |
223,029
-315,605
| -59% | -$6.34M |
|
906
SPS Commerce
SPSC
$4.18B
| $4.47M | ﹤0.01% |
29,388
+7,499
| +34% | +$1.14M |
|
907
Manhattan Associates
MANH
$12.8B
| $4.47M | ﹤0.01% |
28,893
+16,918
| +141% | +$2.62M |
|
908
PPL Corp
PPL
$26.5B
| $4.46M | ﹤0.01% |
160,467
+49,106
| +44% | +$1.36M |
|
909
BorgWarner
BWA
$9.34B
| $4.45M | ﹤0.01% |
103,000
+42,261
| +70% | +$1.83M |
|
910
Dell
DELL
$83.7B
| $4.44M | ﹤0.01% |
110,475
+52,123
| +89% | +$2.1M |
|
|
SLGC
911
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $4.43M | ﹤0.01% |
1,737,814
-4,257,817
| -71% | -$10.9M |
|
912
Bentley Systems
BSY
$16B
| $4.42M | ﹤0.01% |
102,874
+91,024
| +768% | +$3.91M |
|
913
Antero Midstream
AM
$8.79B
| $4.4M | ﹤0.01% |
419,872
-481,987
| -53% | -$5.06M |
|
914
UDR
UDR
$12.7B
| $4.38M | ﹤0.01% |
106,621
-2,224,503
| -95% | -$91.3M |
|
|
DALS
915
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $4.36M | ﹤0.01% |
430,000
+380,000
| +760% | +$3.85M |
|
916
Ulta Beauty
ULTA
$23.1B
| $4.33M | ﹤0.01% |
7,931
+1,716
| +28% | +$936K |
|
|
CIIG
917
DELISTED
CIIG Capital Partners II, Inc. Class A Common Stock
CIIG
| $4.31M | ﹤0.01% |
414,000
-175
| -0% | -$1.82K |
|
918
Performance Food Group
PFGC
$16.3B
| $4.27M | ﹤0.01% |
70,724
+41,287
| +140% | +$2.49M |
|
919
AMN Healthcare
AMN
$751M
| $4.2M | ﹤0.01% |
50,576
+22,586
| +81% | +$1.87M |
|
|
KNSW
920
DELISTED
KnightSwan Acquisition Corporation
KNSW
| $4.18M | ﹤0.01% |
+400,000
| New | +$4.18M |
|
921
Fidelity National Financial
FNF
$16.2B
| $4.18M | ﹤0.01% |
119,535
+62,785
| +111% | +$2.19M |
|
922
Willis Towers Watson
WTW
$32.2B
| $4.17M | ﹤0.01% |
17,951
+3,054
| +21% | +$710K |
|
923
KKR & Co
KKR
$124B
| $4.17M | ﹤0.01% |
79,380
-1,064
| -1% | -$55.9K |
|
924
Navient
NAVI
$1.29B
| $4.17M | ﹤0.01% |
260,623
+229,159
| +728% | +$3.66M |
|
925
Warner Bros
WBD
$31B
| $4.16M | ﹤0.01% |
275,337
-22,579
| -8% | -$341K |
|